NASDAQ · Key Statistics

Denali Therapeutics Inc. (DNLI) Key Statistics

$18.41 NASDAQ: DNLI Market Cap $2.94B

Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for Denali Therapeutics Inc. (DNLI), each with what it measures. Figures are trailing twelve months or the most recent reported period.

Valuation

Metric	Value
P/E ratioShare price divided by earnings per share.	-7.04
P/B ratioShare price divided by book value per share.	4.49
P/S ratioMarket value divided by annual revenue.	880.74
PEG ratioP/E divided by the earnings growth rate.	4.11
EV / EBITDAEnterprise value against earnings before interest, tax, depreciation and amortisation.	-6.03
EV / RevenueEnterprise value against annual revenue.	832.46
Earnings yieldEarnings per share as a percentage of the share price — the inverse of P/E.	-12.42%
Free cash flow yieldFree cash flow as a percentage of market value.	-13.78%

Profitability

Metric	Value
Gross marginRevenue left after the direct cost of goods sold.	-61.04%
Operating marginRevenue left after operating costs.	0.00%
Net marginRevenue left after every cost, including tax and interest.	0.00%
Return on equityProfit as a percentage of shareholders’ equity.	-55.27%
Return on assetsProfit as a percentage of total assets.	-44.17%
Return on capital employedOperating profit against the capital the business uses.	-50.82%

Financial health

Metric	Value
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.	8.37
Quick ratioThe same, excluding inventory.	8.32
Cash ratioCash alone against current liabilities.	2.09
Debt to equityTotal borrowings against shareholders’ equity.	0.03
Debt to assetsTotal borrowings against total assets.	0.03
Interest coverageHow many times operating profit covers the interest bill.	0.00

Per share and size

Metric	Value
Earnings per shareProfit attributable to each share.	$-2.97
Book value per shareShareholders’ equity divided by shares outstanding.	$0.00
Shares outstandingShares currently issued.	0
Market capitalisationShare price times shares outstanding.	$2.94B
Enterprise valueMarket value plus net debt — what it would cost to buy the business outright.	$2.81B

Dividend

Metric	Value
Dividend yieldAnnual dividend as a percentage of the share price.	0.00%

Denali Therapeutics Inc. (DNLI) statistics — frequently asked questions

What is Denali Therapeutics Inc.'s P/E ratio?

Denali Therapeutics Inc. (DNLI) trades on a price-to-earnings ratio of -7.04. A negative P/E means the company reported a loss, so the ratio is not a meaningful valuation measure.

What is Denali Therapeutics Inc.'s return on equity?

Denali Therapeutics Inc. (DNLI) reports a return on equity of -55.27%, meaning it generated that much profit for every dollar of shareholders' equity.

How much debt does Denali Therapeutics Inc. carry?

Denali Therapeutics Inc. (DNLI) has a debt-to-equity ratio of 0.03, which compares total borrowings with shareholders' equity.

Related stock screens

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks High ROE Stocks Low P/E Stocks High Net Margin Stocks Dividend Stocks Low Debt Stocks Nasdaq High ROE Stocks All stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.